News

July is for barbecues, fireworks, and vacations. Many people don't want to think too hard about anything. Three Fool.com contributors think they have solutions for those investors who don't want to

Dividend stocks pay you regularly regardless of how the share price fluctuates. Ideally, of course, the share price will move steadily higher over time and make you money in two ways.

The good news

Billionaire investors don't necessarily need quarterly payments from dividend stocks to cover their day-to-day expenses, but they buy them anyway. That's because businesses that distribute a portion

The past few years have been tough ones for investors holding shares of Pfizer (NYSE: PFE). The Big Pharma stock is down by more than half from the peak it set in late 2021.

Pfizer's stock price was

On June 20, the Food and Drug Administration (FDA) gave Sarepta Therapeutics (NASDAQ: SRPT) exactly what it wanted. The agency upgraded the status of its gene therapy for Duchenne muscular dystrophy

The benchmark S&P 500 index keeps breaking new records thanks in large part to a handful of stocks at the top. Luckily for income-seeking investors, there are some highly reliable dividend stocks

Vertex Pharmaceuticals (NASDAQ: VRTX) transformed the world of cystic fibrosis (CF) treatment when it launched its first product for the disease 12 years ago. Since then, it's built a CF treatment

Investing in equity markets is a reliable, wealth-growing strategy. In the past 33 years, the S&P 500's average annual return is about 10.6%. It's hard to find a return much better than that

Eli Lilly (NYSE: LLY) has become a big name in the anti-obesity market with the recent approval of Zepbound, which is likely to rake in billions in revenue alongside Mounjaro, the company's diabetes

With Vertex Pharmaceuticals (NASDAQ: VRTX) announcing on June 21 that its therapy VX-880 helped nearly all of the patients with diabetes in a clinical trial to reduce or eliminate their need for

Over the past two decades, the road has been rocky for AT&T (NYSE: T) investors, with the stock price only up close to 5% (not including dividends). This year has been a much-appreciated change of

Ultra-high-yield dividend stocks, or companies with annualized payouts above the 5% mark, tend to underperform the broader markets over periods of less than five years. The core reason is that an

When a company obtains positive news from the Food and Drug Administration (FDA), such as the approval of a treatment or a label expansion, it can mark a milestone for the business and lead to

A few years ago, Eli Lilly (NYSE: LLY) was far from the hottest stock in the biopharmaceutical world. But times have changed. Today, Lilly ranks as the biggest healthcare company in the world. It

Most investors know the phrase "buy low, sell high." It's a fine piece of investing wisdom, but it isn't as straightforward as it seems. Even a company whose shares are performing well can be

ResMed has had the market on sleep apnea cornered for a while, but new weight loss drugs might be creeping in. In this podcast, we look at what could change based on recent studies and some other

U.S. wireless carrier AT&T (NYSE: T) is a polarizing stock among investors. Shares are down nearly 30% in price over the past decade, which is a tough pill to swallow. However, include AT&T's famous

Pfizer (NYSE: PFE) can be a polarizing stock to own right now. Its future remains hazy given that it is facing some troubling patent cliffs and revenue from its COVID-19 vaccine is dwindling. But at

It's been a big year for most stocks, with the S&P 500 index up about 24% over the past 12 months. A rising market is wonderful for the stocks already in your portfolio, but finding new investment

Few biotech companies have made more noise than Viking Therapeutics (NASDAQ: VKTX) this year, and that's saying something. The drugmaker had been a relatively small and unknown player in the